Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 18/20 | 0.72 |
| ▸ | CCNA2 | P20248 | 16/20 | 0.72 |
| ▸ | CDK2 | P24941 | 16/20 | 0.72 |
| ▸ | CCNA1 | P78396 | 16/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30757838 | 0.84 | CHEK1 (1.00) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL16784468 | 0.84 | CHEK1 (1.00) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL14050869 | 0.81 | CHEK1 (0.70) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL16784469 | 0.81 | CHEK1 (0.73) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL14413740 | 0.81 | CHEK1 (0.73) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL14542953 | 0.78 | CHEK1 (0.73) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL17826802 | 0.78 | CHEK1 (0.57) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL14543105 | 0.76 | CHEK1 (0.77) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL16784500 | 0.76 | CHEK1 (0.77) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL14543108 | 0.74 | CHEK1 (0.77) | CHEK1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931677-B1 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-04-20 | — | — | EP | disclosed |
| US-8586576-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-09-27 | — | — | US | disclosed |
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-09-27 | — | — | US | disclosed |
| WO-2007044449-A2 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | CHEK1 58/4885CCNA2 29/4885CDK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.